About Niall Hodgins

This author has not yet filled in any details.
So far Niall Hodgins has created 5 blog entries.

SeraNovo Awarded MIT R&D Collaboration Grant

By |2018-01-24T14:27:55+00:00January, 2018|

The Province of South Holland has awarded a subsidy of €200.000 to a joint project between SeraNovo and Percuros, with consultancy from Good Biomarker Sciences. The project allows SeraNovo to further develop their technology platform, while testing it on the advanced test Percuros will develop.

SeraNovo’s technology allows new medicines to be absorbed in the human body that previously could not. Over time this will create a new wave of medications in fields including Cancer, HIV and Arthritis.

The test of Percuros will be safer and cheaper than commercially available tests, while granting SeraNovo one of the best testing platforms for simulating the human gastro-intestinal tract to optimise their technology and prove its efficacy. Combining these two innovations will allow SeraNovo to bring more cures to patients and come one step closer to solving a big problem the pharmaceutical industry has with declining solubility of newly developed medicines.

 

         

 

 

SeraNovo Files Patent

By |2018-01-24T14:28:56+00:00January, 2018|

SeraNovo has officially filed its first patent with the assistance of Harrie Marsman of V.O. Patents and Trademarks.

Detailed in the patent is the method, developed by SeraNovo, to design a liquid formulation specifically for a single medicine. SeraNovo’s technology allows new medicines to be absorbed in the human body that previously could not. Over time this will create a new wave of medications in fields including Cancer, HIV and Arthritis.

This first patent forms the foundation of SeraNovo’s protection strategy and will be built upon in the near future. We look forward to a fruitful collaboration with V.O. in the coming years.

Enterprise Leiden Fund Loan

By |2017-08-15T10:08:56+00:00February, 2017|

SeraNovo has acquired a €30,000 loan from the Enterprise Leiden Fund to develop our drug formulation platform. The loan is to be used to develop the second phase of the technology with a view to creating a market ready service with and ultimately a product line in the coming years.

The Enterprise Leiden Fund was set up by Luris to help companies, such as SeraNovo, to bring breakthrough innovations to the market. One member of the judging panel noted, ‘SeraNovo have an excellent technology capable of solving very difficult technical challenges in the pharmaceutical industries. We have every confidence in the team they have assembled and expect their impressive rate of development to continue.’

Bastiaan Kluft joins SeraNovo as partner

By |2017-10-26T13:17:58+00:00September, 2016|

Bastiaan Kluft, who has a background in Chemistry & Science Based Business, is joining SeraNovo as of the start of September 2016. He previously worked for 1,5 years at KPN as a management trainee, increasing his business and managerial skills to complement the scientific knowledge obtained at Leiden University. His Chemistry studies were focused mostly on organic chemistry, biological analysis and protein interactions. In SeraNovo Bastiaan’s focus will lie mostly on the scientific and R&D part of the technology, close to the business side, fulfilling the role of CSO within SeraNovo.

SeraNovo wins Gulliver prize for Best Student Entrepreneur 2016

By |2017-08-15T13:30:23+00:00June, 2016|

SeraNovo won the prestigious Gulliver prize amongst fierce competition between startups. The student entrepreneur competition, set up by Science meets Business and Lugus, focuses on stimulating startups in the Leiden BioScience Park and region. SeraNovo blew away the jury with his pitch on the solution for the preclinical solubility problems of the pharmaceutical industry. The prize money of €10.000,- will be put to good use in the further development of SeraNovo. Read more about the Gulliver competition on the Leiden University website or the Gulliver website.